drugset
drugset / Trial / NCT06199908

AMT-562 in Patients With Selected Advanced Solid Tumors

NCT06199908 ↗

Phase 1 Unknown 72 enrolled Multitude Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This is a first-in-human, non-randomized, open-label, multicenter Phase 1 study of AMT-562 in patients with advanced solid tumors.

Timeline

Start
2024-05-20
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AMT-562 Unknown — Intravenous

Indications

cancer